These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 7828604

  • 1. Soluble interleukin-2 receptors and CA 125 in ovarian cancer, a longitudinal and cross-sectional study.
    Burch D, Metcalfe S, Gallagher G, al-Azzawi F, Wheeler T.
    Eur J Gynaecol Oncol; 1994; 15(5):352-8. PubMed ID: 7828604
    [No Abstract] [Full Text] [Related]

  • 2. Elevated ovarian cancer marker (CA-125) in cirrhotic patients with intractable ascites.
    Zamir D, Jarchovsky J, Singer C, Weiner P.
    J Clin Gastroenterol; 1998 Sep; 27(2):154-5. PubMed ID: 9754780
    [No Abstract] [Full Text] [Related]

  • 3. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Mills GB.
    Cancer; 1995 Nov 01; 76(9):1615-20. PubMed ID: 8635066
    [Abstract] [Full Text] [Related]

  • 4. An unusual abdominal cystic mass.
    Montaruli E, Branchereau S.
    J Pediatr Hematol Oncol; 2012 Nov 01; 34(8):641; answer 642. PubMed ID: 23018573
    [Abstract] [Full Text] [Related]

  • 5. Soluble IL-2 alpha and ovarian cancer.
    Barton DP.
    Br J Cancer; 1994 Mar 01; 69(3):622-3. PubMed ID: 8123502
    [No Abstract] [Full Text] [Related]

  • 6. The clinical value of tumour markers in the management of ovarian cancer.
    Rustin GJ.
    Ann Clin Biochem; 1996 Jul 01; 33 ( Pt 4)():284-9. PubMed ID: 8836386
    [No Abstract] [Full Text] [Related]

  • 7. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
    Selman AE, Copeland LJ.
    Curr Oncol Rep; 1999 Sep 01; 1(1):71-6. PubMed ID: 11122801
    [Abstract] [Full Text] [Related]

  • 8. Ovarian fibroma with marked ascites and elevated serum levels of CA-125 in a young girl.
    Sugiyama A, Urushihara N, Fukumoto K, Fukuzawa H, Nagae H, Watanabe K, Mitsunaga M, Hasegawa S, Koyama M.
    J Pediatr Surg; 2011 May 01; 46(5):1001-4. PubMed ID: 21616270
    [Abstract] [Full Text] [Related]

  • 9. Is CA 125 actually a tumor marker for ovarian cancer?
    Collazos J.
    Acta Oncol; 1995 May 01; 34(2):268. PubMed ID: 7718270
    [No Abstract] [Full Text] [Related]

  • 10. A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not.
    Dorizzi RM, Meneghelli S, Rocca M, Ferrari A.
    Clin Chem Lab Med; 2006 May 01; 44(11):1386-7; author reply 1388. PubMed ID: 17087656
    [No Abstract] [Full Text] [Related]

  • 11. Screening for Ovarian Cancer with CA 125 and Ultrasound Algorithm Does Not Reduce Mortality.
    Ebell MH.
    Am Fam Physician; 2021 Oct 01; 104(4):422-423. PubMed ID: 34652113
    [No Abstract] [Full Text] [Related]

  • 12. Origin of ovarian cancer may have implications for screening.
    Tuma RS.
    J Natl Cancer Inst; 2010 Jan 06; 102(1):11-3. PubMed ID: 20023201
    [No Abstract] [Full Text] [Related]

  • 13. Limitations to the use of the CA-125 antigen level in ovarian cancer.
    Markman M.
    Curr Oncol Rep; 2003 Jul 06; 5(4):263-4. PubMed ID: 12781066
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.